What question did this study set out to answer?

To evaluate the effectiveness of gilteritinib maintenance therapy in patients with relapsed/refractory acute myeloid leukemia after allogeneic transplantation.

June 4, 2026Blood ResearchOpen Access

Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations

View Full Paper

Ask AI

Bookmark

Authors

YLYun-Tzu LinNational Taiwan University Hospital XTXavier Cheng-Hong TsaiNational Taiwan University Hospital FTFeng‐Ming TienNational Taiwan University

Discussion

Member takes

Implication

Real-world experience shows gilteritinib improves survival in FLT3-mutated AML after transplantation, suggesting its efficacy as maintenance therapy.

Key Points

To evaluate the effectiveness of gilteritinib maintenance therapy in patients with relapsed/refractory acute myeloid leukemia after allogeneic transplantation.
Patients with FLT3-mutated relapsed/refractory AML received gilteritinib before transplantation.
Posttransplant maintenance was offered to those achieving engraftment without significant acute graft-versus-host disease.
Follow-up duration was a median of 46.2 months.
The cohort achieved a complete response rate of 76.2%.
Gilteritinib maintenance therapy was associated with longer relapse-free and overall survival.
There was a significantly lower 1-year cumulative incidence of relapse.

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a21164cd499ed480b16f45d https://doi.org/10.1007/s44313-026-00144-3

View Full Paper

Ask AI

Bookmark

Implication

Real-world experience shows gilteritinib improves survival in FLT3-mutated AML after transplantation, suggesting its efficacy as maintenance therapy.

Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider